Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Accounts Payables: 2023-2025

Historic Accounts Payables for Zenas BioPharma (ZBIO) over the last 1 years, with Sep 2025 value amounting to $6.4 million.

  • Zenas BioPharma's Accounts Payables fell 57.27% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year decrease of 57.27%. This contributed to the annual value of $17.1 million for FY2024, which is 217.57% up from last year.
  • Per Zenas BioPharma's latest filing, its Accounts Payables stood at $6.4 million for Q3 2025, which was down 18.75% from $7.9 million recorded in Q2 2025.
  • Zenas BioPharma's 5-year Accounts Payables high stood at $20.0 million for Q1 2025, and its period low was $5.4 million during Q4 2023.
  • Its 3-year average for Accounts Payables is $12.0 million, with a median of $11.5 million in 2024.
  • Per our database at Business Quant, Zenas BioPharma's Accounts Payables soared by 217.57% in 2024 and then crashed by 57.27% in 2025.
  • Zenas BioPharma's Accounts Payables (Quarterly) stood at $5.4 million in 2023, then skyrocketed by 217.57% to $17.1 million in 2024, then slumped by 57.27% to $6.4 million in 2025.
  • Its Accounts Payables stands at $6.4 million for Q3 2025, versus $7.9 million for Q2 2025 and $20.0 million for Q1 2025.